Peers: MDGL VKTX BMRN AXSM KRYS RYTM ALNY INCY KROS NBIX

| Held by: CGMM IBB VHT SBIO ESML ONEQ FHLC GURU DRKY FMED

Index	-
Market Cap	2.68B
Enterprise Value	2.05B
Income	-259.50M
Sales	7.12M
Book/sh	5.37
Cash/sh	5.31
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	100
IPO	Feb 08, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	376.91
P/B	4.18
P/C	4.22
P/FCF	-
EV/EBITDA	-
EV/Sales	287.71
Quick Ratio	9.03
Current Ratio	9.03
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.18
EPS next Y	-1.56
EPS next Q	-0.49
EPS this Y	-9.77%
EPS next Y	17.38%
EPS next 5Y	37.43%
EPS past 3/5Y	-12.98% -
Sales past 3/5Y	-39.71% -
EPS Y/Y TTM	-35.06%
Sales Y/Y TTM	-88.87%
EPS Q/Q	-254.88%
Sales Q/Q	-80.67%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	-9.17% 31.56%

Insider Own	36.21%
Insider Trans	-0.86%
Inst Own	69.27%
Inst Trans	-2.46%
ROA	-34.16%
ROE	-36.81%
ROIC	-41.09%
Gross Margin	96.57%
Oper. Margin	-3432.20%
Profit Margin	-3644.21%
SMA20	-1.88%
SMA50	-11.95%
SMA200	-27.81%
Trades

Shs Outstand	117.65M
Shs Float	76.26M
Short Float	20.54%
Short Ratio	11.80
Short Interest	15.66M
52W High	42.21 -46.81%
52W Low	21.02 6.80%
Volatility	6.31% 6.42%
ATR (14)	1.35
RSI (14)	39.97
Beta	0.12
Rel Volume	0.62
Avg Volume	1.33M
Volume	81,443

Perf Week	-4.79%
Perf Month	-13.15%
Perf Quarter	-39.31%
Perf Half Y	-34.20%
Perf YTD	-36.00%
Perf Year	-26.80%
Perf 3Y	180.63%
Perf 5Y	128.15%
Perf 10Y	-
Recom	1.12
Target Price	51.27
Prev Close	23.20
Price	22.45
Change %	-3.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-26	Initiated	BMO Capital Markets	Outperform	$58
Mar-18-26	Initiated	Truist	Buy	$57
Oct-20-25	Resumed	H.C. Wainwright	Buy	$52
Aug-25-25	Initiated	Wells Fargo	Overweight	$45
Jul-17-25	Initiated	Goldman	Neutral	$27
Jun-17-25	Initiated	Citigroup	Buy	$42
Jun-10-25	Initiated	Stifel	Buy	$44
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight	$42
Dec-30-24	Initiated	H.C. Wainwright	Buy	$48
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$35
Jan-18-24	Initiated	Guggenheim	Buy	$30
Jan-16-24	Initiated	Piper Sandler	Overweight	$37
Oct-30-23	Initiated	RBC Capital Mkts	Outperform	$25

Show Previous Ratings

Oct-02-26 06:02PM	Group 1 Automotive and 4 More Stocks See Action From Activist Investors (Barrons.com)
04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-26 08:00AM	NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease (GlobeNewswire)
Sep-21-26 10:57AM	Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) (PR Newswire)
09:00AM	NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) (GlobeNewswire)
12:07PM	Loading…
Sep-08-26 12:07PM	Novartis Trial Failure Sparks Biopharma Options Frenzy (Schaeffer's Research)
09:53AM	Novartis's failed trial for cholesterol drug leads to broad biopharma selloff (MarketWatch)
Sep-03-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-26 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-26-26 08:00AM	NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 (GlobeNewswire)
Aug-06-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-26 07:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Jul-29-26 08:00AM	NewAmsterdam Pharma to Host Investor Day on August 5, 2026 (GlobeNewswire)
Jul-24-26 10:13AM	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) (PR Newswire)
Jul-02-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Jul-01-26 08:00AM	NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 (GlobeNewswire)
Jun-03-26 08:00AM	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions (GlobeNewswire)
May-28-26 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-11-26 08:41AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May (GlobeNewswire)
May-07-26 07:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire) +12.46%
May-01-26 04:57PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Apr-08-26 08:00AM	NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-26 05:43PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-23-26 08:00AM	NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session (GlobeNewswire)
Mar-06-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-25-26 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-18-26 07:00AM	NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-14-26 08:04AM	NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit (MarketBeat)
Feb-06-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.99%
Feb-04-26 08:00AM	NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
08:00AM	Loading…
Jan-09-26 08:00AM	NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities (GlobeNewswire)
Jan-06-26 07:54AM	NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 (Insider Monkey)
Jan-05-26 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-25 06:50PM	National Presto, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
Dec-05-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-07-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.01%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-25 08:20AM	Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-30-25 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November (GlobeNewswire) +8.05%
Oct-29-25 10:00AM	NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-24-25 07:31AM	Enteras oral osteoporosis drug meets endpoints in Phase II trial (Clinical Trials Arena)
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) +12.26%
Oct-07-25 06:04AM	NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-24-25 08:00AM	NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Aug-29-25 04:30PM	Core Scientific, NewAmsterdam Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-25-25 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September (GlobeNewswire)
Aug-18-25 08:00AM	NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib (GlobeNewswire)
Aug-06-25 08:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
07:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Jul-30-25 08:25AM	NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 (GlobeNewswire)
Jul-22-25 08:00AM	NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 (GlobeNewswire)
Jul-16-25 09:38AM	Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) (Insider Monkey)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com) -6.38%
Jun-11-25 08:06PM	NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel (Insider Monkey) -6.14%
Jun-09-25 07:00AM	NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial (GlobeNewswire)
Jun-05-25 08:00AM	NewAmsterdam Pharma to Host R&D Day on June 11, 2025 (GlobeNewswire)
May-27-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-14-25 08:00AM	NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference (GlobeNewswire)
May-12-25 09:55AM	Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know (Zacks)
May-08-25 09:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:15AM	Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates (Zacks)
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-07-25 07:15AM	NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 (GlobeNewswire)
May-02-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-25 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress (GlobeNewswire)
Apr-29-25 11:40AM	NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 01:01PM	Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-17-25 04:01PM	NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors (GlobeNewswire)
Apr-11-25 04:23PM	NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey) +8.60%
Apr-04-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.17%
Mar-31-25 04:18PM	Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? (Investor's Business Daily) -5.93% -10.21%
08:00AM	NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
Feb-26-25 08:00AM	NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.23%
Feb-25-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-07-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-25 08:00AM	NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-10-25 08:00AM	NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities (GlobeNewswire)
Jan-09-25 03:38PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-24 05:16PM	NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-11-24 09:37PM	NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
Dec-10-24 05:10PM	NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug (Investor's Business Daily) +41.41%
04:34PM	NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Dec-06-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-24 07:37AM	NewAmsterdam Pharma Reports Promising Phase 3 Trial Results (TipRanks)
Nov-20-24 04:13PM	NewAmsterdam Dives And Sacrifices A Cup Base Despite A Winning Cholesterol Study (Investor's Business Daily) -15.50%
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH (GlobeNewswire)
Nov-18-24 03:20PM	NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-06-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire) +13.73%
Nov-01-24 05:26PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-24 04:30PM	NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November (GlobeNewswire)
Oct-04-24 04:30PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-24 04:32PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-07-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Aug-02-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.35%

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Facp.Dr. Michael Harvey Davidson FACC

M.D.Dr. Johannes Jacob Pieter Kastelein FESC

Chief Financial OfficerMr. Mayur Amrat Somaiya

CGMAMr. Robert W. Gunning CPA

Executive VP & Head of Investor RelationsMr. Matthew Philippe

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Sep 30 '26	Sale	25.03	50,246	1,257,657	69,302	Oct 02 04:30 PM
Davidson Michael H.	Chief Executive Officer	Sep 14 '26	Buy	22.65	10,000	226,500	792,923	Sep 15 04:30 PM
Smither John W	Director	Sep 04 '26	Sale	25.32	1,600	40,512	8,760	Sep 09 04:30 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Aug 24 '26	Sale	26.91	125,000	3,363,750	69,302	Aug 25 04:30 PM
Kastelein Johannes Jacob Piete	Affiliate	Aug 24 '26	Proposed Sale	27.87	125,000	3,483,750		Aug 24 04:55 PM
Kooij Louise Frederika	Chief Accounting Officer	Jul 20 '26	Option Exercise	11.34	105,000	1,191,100	129,353	Jul 22 04:05 PM
Kooij Louise Frederika	Chief Accounting Officer	Jul 20 '26	Sale	30.34	105,000	3,185,656	24,353	Jul 22 04:05 PM
Kooij Louise Frederika	Chief Accounting Officer	Jun 22 '26	Option Exercise	11.28	40,000	451,000	64,353	Jun 24 04:10 PM
Kooij Louise Frederika	Chief Accounting Officer	Jun 22 '26	Sale	30.20	40,000	1,208,159	24,353	Jun 24 04:10 PM
Kooij Louise Frederika	Chief Accounting Officer	May 26 '26	Option Exercise	10.07	65,000	654,500	89,353	May 27 04:30 PM
Kooij Louise Frederika	Chief Accounting Officer	May 26 '26	Sale	35.69	65,000	2,319,850	24,353	May 27 04:30 PM
Louise Kooij	Officer	May 26 '26	Proposed Sale	35.44	210,000	7,442,400		May 26 05:04 PM
LANGE LOUIS G	Director	Mar 11 '26	Sale	30.42	44,619	1,357,230	10,360	Mar 12 04:25 PM
Louis G. Lange	Affiliate	Mar 11 '26	Proposed Sale	31.27	44,619	1,395,236		Mar 11 04:08 PM
LANGE LOUIS G	Director	Mar 06 '26	Sale	29.41	28,186	828,950	0	Mar 10 08:58 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 05 '26	Sale	30.30	104,467	3,165,350	69,302	Mar 09 08:18 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 09 '26	Sale	30.29	101,409	3,071,679	69,302	Mar 09 08:18 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 06 '26	Sale	30.32	94,124	2,853,840	69,302	Mar 09 08:18 PM
Louis G. Lange	Affiliate	Mar 06 '26	Proposed Sale	31.18	28,186	878,839		Mar 06 05:52 PM
Kastelein Johannes Jacob Piete	Affiliate	Mar 02 '26	Proposed Sale	31.18	300,000	9,354,000		Mar 05 04:14 PM
Davidson Michael H.	Chief Executive Officer	Mar 02 '26	Sale	33.25	443,707	14,753,258	174,144	Mar 02 06:08 PM
Michael H. Davidson	Affiliate	Mar 02 '26	Proposed Sale	35.46	443,707	15,733,850		Mar 02 04:10 PM
Davidson Michael H.	Chief Executive Officer	Feb 26 '26	Sale	33.71	183,332	6,179,974	174,144	Feb 26 09:40 PM
Davidson Michael H.	Chief Executive Officer	Feb 24 '26	Sale	36.15	64,708	2,338,943	459,859	Feb 26 09:40 PM
Davidson Michael H.	Chief Executive Officer	Feb 25 '26	Sale	35.30	58,253	2,056,174	459,859	Feb 26 09:40 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Feb 20 '26	Sale	35.31	45,481	1,605,998	53,500	Feb 24 04:40 PM
Michael H. Davidson	Affiliate	Feb 24 '26	Proposed Sale	36.17	750,000	27,127,500		Feb 24 04:22 PM
Kastelein Johannes Jacob Piete	Officer	Feb 20 '26	Proposed Sale	34.63	45,481	1,575,007		Feb 20 07:51 AM
Kooij Louise Frederika	Chief Accounting Officer	Jan 27 '26	Option Exercise	10.90	39,816	433,994	64,169	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 28 '26	Option Exercise	10.90	32,612	355,471	56,965	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 27 '26	Sale	32.62	39,816	1,298,798	24,353	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 28 '26	Sale	31.80	32,612	1,037,062	24,353	Jan 29 04:40 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 23 '26	Option Exercise	10.90	38,172	416,075	62,525	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 26 '26	Option Exercise	10.90	34,400	374,960	58,753	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 23 '26	Sale	33.75	38,172	1,288,345	24,353	Jan 27 05:38 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 26 '26	Sale	32.78	34,400	1,127,498	24,353	Jan 27 05:38 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 20 '26	Option Exercise	9.26	60,216	557,600	118,598	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 21 '26	Option Exercise	9.26	39,784	368,400	98,166	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 20 '26	Sale	31.96	60,216	1,924,401	58,382	Jan 22 05:24 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 21 '26	Sale	33.59	39,784	1,336,217	58,382	Jan 22 05:24 PM
Mayur Somaiya	Affiliate	Jan 20 '26	Proposed Sale	31.65	200,000	6,330,000		Jan 20 04:17 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Jan 05 '26	Sale	33.25	6,000	199,500	73,481	Jan 07 06:31 PM
Kooij Louise Frederika	Chief Accounting Officer	Jan 05 '26	Sale	33.25	2,647	88,013	12,353	Jan 07 06:27 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 05 '26	Sale	33.25	5,118	170,174	32,882	Jan 07 06:27 PM
Michael Davidson	affiliate	Jan 07 '26	Proposed Sale	35.48	11,582	410,889		Jan 07 01:19 PM
Douglas F Kling	Affiliate	Jan 06 '26	Proposed Sale	33.48	300,000	10,044,000		Jan 06 04:29 PM
Louise Kooij	affiliate	Jan 05 '26	Proposed Sale	33.25	2,647	88,012		Jan 05 03:18 PM
Johannes Kastelein	Affiliate	Jan 05 '26	Proposed Sale	33.25	6,000	199,499		Jan 05 03:04 PM
Mayur Ian Somaiya	affiliate	Jan 05 '26	Proposed Sale	33.25	5,118	170,173		Jan 05 03:03 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 23 '25	Option Exercise	10.00	75,117	751,170	90,117	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 26 '25	Option Exercise	10.10	43,872	443,220	58,872	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 24 '25	Option Exercise	10.00	26,011	260,110	41,011	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 23 '25	Sale	36.21	75,117	2,719,987	15,000	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 26 '25	Sale	35.30	43,872	1,548,682	15,000	Dec 29 05:14 PM
Kooij Louise Frederika	Chief Accounting Officer	Dec 24 '25	Sale	35.68	26,011	928,072	15,000	Dec 29 05:14 PM
Louise Kooij	Officer	Dec 23 '25	Proposed Sale	36.49	290,000	10,582,100		Dec 23 05:31 PM
Bain Capital Life Sciences Fun	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	267,429	10,250,554		Dec 02 09:25 PM
BCLS II Investco, LP	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	4,500,000	172,485,000		Dec 02 09:23 PM
BCIP Life Sciences Associates,	Former Affiliate	Dec 02 '25	Proposed Sale	38.33	32,571	1,248,446		Dec 02 09:22 PM

Open in Screener

GNLX

Genelux Corp

2.53

Oct 05 • 9:49 AM ET -0.03 (-1.17%)

Healthcare Biotechnology USA Micro NASD

Peers: CNTB GALT IMUX IPHA KZIA SPRO VRCA VTVT AGEN ALPS

| Held by: VTI VXF IWC BTEC CHNA

Index	-
Market Cap	114.47M
Enterprise Value	98.22M
Income	-35.60M
Sales	0.01M
Book/sh	0.36
Cash/sh	0.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	26
IPO	Jan 26, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	11447.26
P/B	7.08
P/C	6.13
P/FCF	-
EV/EBITDA	-
EV/Sales	9822.26
Quick Ratio	2.39
Current Ratio	2.39
Debt/Eq	0.15
LT Debt/Eq	0.13
Option/Short	Yes / Yes

EPS (ttm)	-0.87
EPS next Y	-0.75
EPS next Q	-0.20
EPS this Y	5.23%
EPS next Y	7.77%
EPS next 5Y	44.13%
EPS past 3/5Y	-59.75% -8.40%
Sales past 3/5Y	-91.03% -
EPS Y/Y TTM	-1.31%
Sales Y/Y TTM	0.00%
EPS Q/Q	-7.23%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-6.76% -

Insider Own	14.05%
Insider Trans	-1.32%
Inst Own	31.02%
Inst Trans	0.94%
ROA	-121.80%
ROE	-177.93%
ROIC	-195.51%
Gross Margin	-5925.00%
Oper. Margin	-455275.00%
Profit Margin	-444950.00%
SMA20	1.01%
SMA50	-4.00%
SMA200	-10.69%
Trades

Shs Outstand	45.10M
Shs Float	38.89M
Short Float	10.53%
Short Ratio	15.34
Short Interest	4.10M
52W High	8.53 -70.36%
52W Low	2.29 10.48%
Volatility	4.00% 5.30%
ATR (14)	0.13
RSI (14)	48.61
Beta	0.58
Rel Volume	0.57
Avg Volume	266.98K
Volume	15,125

Perf Week	2.43%
Perf Month	0.40%
Perf Quarter	-14.81%
Perf Half Y	-7.33%
Perf YTD	-41.97%
Perf Year	-43.15%
Perf 3Y	-89.77%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	18.83
Prev Close	2.56
Price	2.53
Change %	-1.17%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Lake Street	Buy	$16
Oct-29-24	Initiated	Guggenheim	Buy	$8
Aug-28-24	Initiated	ROTH MKM	Buy	$10
Nov-27-23	Initiated	H.C. Wainwright	Buy	$35
Sep-12-23	Initiated	Maxim Group	Buy	$40
Feb-15-23	Initiated	The Benchmark Company	Speculative Buy	$10

Sep-09-26 04:01PM	Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy (GlobeNewswire)
Aug-13-26 04:20PM	Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates (GlobeNewswire)
Jun-30-26 08:00AM	Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi-Vec in Ovarian Cancer (GlobeNewswire)
May-07-26 04:15PM	Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates (GlobeNewswire) +9.89%
Mar-19-26 04:15PM	Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.51%
08:00AM	Loading…
Feb-18-26 08:00AM	Genelux Corporation to Participate in Upcoming Conferences (GlobeNewswire)
Jan-12-26 04:00PM	Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners (GlobeNewswire) -5.36%
Jan-08-26 09:13AM	Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.76%
Jan-07-26 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-05-26 08:00AM	Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials (GlobeNewswire) -23.52%
Jan-02-26 08:00AM	Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-26-25 08:00AM	Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.67%
Nov-05-25 04:20PM	Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -32.40%
Sep-02-25 04:01PM	Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-07-25 04:20PM	Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -6.96% -5.69%
07:00AM	Loading…
Jul-07-25 07:00AM	Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development (GlobeNewswire)
Jun-02-25 12:00PM	Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know (Zacks)
May-06-25 04:10PM	Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -7.17%
May-01-25 04:05PM	Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire) -9.85% +8.45%
Apr-18-25 09:40AM	Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 04:10PM	Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -12.34%
09:35AM	Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Mar-25-25 08:31AM	Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.60%
08:30AM	Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease (GlobeNewswire)
08:30AM	Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer (GlobeNewswire)
Mar-02-25 09:39AM	Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-03-25 06:45AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) -10.63%
Dec-13-24 07:01AM	Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright (GlobeNewswire) -7.54%
Nov-15-24 09:50AM	These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts (TipRanks) -19.73%
Nov-14-24 04:05PM	Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
04:01PM	Loading…
Nov-06-24 04:01PM	Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-25-24 01:01PM	Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp (GuruFocus.com)
Oct-23-24 11:27AM	Genelux doses first subject in Phase II trial of NSCLC treatment (Clinical Trials Arena)
Oct-22-24 04:01PM	Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-09-24 04:15PM	Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-03-24 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.94%
Aug-14-24 09:54PM	GNLX Stock Earnings: Genelux Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-12-24 05:16PM	Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds (Insider Monkey) -6.57%
Jul-30-24 07:00AM	Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 (GlobeNewswire)
May-24-24 08:00AM	Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants (GlobeNewswire) -43.04%
May-23-24 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire) -5.35%
May-09-24 11:53PM	GNLX Stock Earnings: Genelux Misses EPS for Q1 2024 (InvestorPlace) +6.07%
04:25PM	Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Apr-26-24 09:35AM	Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-23-24 09:35AM	Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-05-24 09:35AM	After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX) (Zacks)
Apr-04-24 12:00PM	All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy (Zacks)
Apr-02-24 07:52AM	GNLX Stock Earnings: Genelux Misses EPS for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -18.51%
Dec-15-23 03:01PM	Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX) (GuruFocus.com) -13.23%
Nov-27-23 07:00AM	Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer (GlobeNewswire)
Nov-14-23 05:50PM	Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire) -7.61%
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-19-23 03:01PM	Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX) (GuruFocus.com) +8.04%
Sep-15-23 03:03PM	Director John Smither Sells 900 Shares of Genelux Corp (GNLX) (GuruFocus.com)
Sep-14-23 01:21PM	10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX) (GuruFocus.com)
07:00AM	Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.69%
Aug-28-23 07:00AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) +11.01%
Aug-14-23 07:00AM	Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-02-23 04:00PM	Genelux Corporation to Participate in Fireside Chat at BTIGs Virtual Biotechnology Conference 2023 (GlobeNewswire) +5.52%
01:08AM	10 Recent IPOs in 2023 to Consider (Insider Monkey)
Jul-28-23 10:54AM	Why Shares of Genelux Climbed This Week (Motley Fool) -9.38%
Jul-20-23 04:45PM	Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires (GlobeNewswire) -10.85% -15.77%
Jul-10-23 07:00AM	Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology (GlobeNewswire)
Jun-29-23 07:00AM	Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC (GlobeNewswire)
Jun-22-23 07:00AM	Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023 (GlobeNewswire) -7.05%
Jun-12-23 07:00AM	Genelux Corporation Announces $18 Million Private Placement (GlobeNewswire) +7.58%
Jun-01-23 05:19PM	Why Shares of Genelux Corporation Jumped This Week (Motley Fool) +6.62%
May-25-23 04:01PM	Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology (GlobeNewswire) +6.62%
May-15-23 07:00AM	Genelux Corporation Announces $33 Million Private Placement (GlobeNewswire) -9.06%
Mar-23-23 07:00AM	Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023 (GlobeNewswire)
Jan-25-23 09:00PM	Genelux Corporation Announces Pricing of Initial Public Offering (GlobeNewswire)

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay on September 4, 2001 and is headquartered in Westlake Village, CA.

ChairmanMr. Thomas D. Zindrick J.D.

CFO and Principal Financial & Accounting OfficerMr. Matthew Pulisic M.B.A.

Chief Technical OfficerDr. Joseph Cappello Ph.D.

Chief Scientific OfficerDr. Yong Yu Ph.D.

General CounselMr. Eric Groen J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cappello Joseph	Chief Technical Officer	Aug 31 '26	Sale	2.74	10,257	28,112	318,480	Sep 02 07:05 PM
Zindrick Thomas	President and CEO	Aug 31 '26	Sale	2.67	34,463	91,899	1,226,427	Sep 02 07:05 PM
Yu Yong	Chief Scientific Officer	Aug 31 '26	Sale	2.75	9,683	26,658	258,688	Sep 02 07:05 PM
Yu Yong	Chief Scientific Officer	Aug 04 '26	Sale	2.94	653	1,922	268,371	Aug 04 08:20 PM
Cappello Joseph	Chief Technical Officer	Aug 04 '26	Sale	2.95	653	1,924	328,737	Aug 04 08:20 PM
Zindrick Thomas	President and CEO	Aug 04 '26	Sale	2.95	3,023	8,905	1,260,890	Aug 04 08:20 PM
Smither John W	Director	Jul 01 '26	Sale	2.91	12,000	34,898	91,403	Jul 02 04:35 PM
JOHN SMITHER	Director	Jul 01 '26	Proposed Sale	2.91	12,000	34,898		Jul 01 06:16 PM
Smalling Ralph	Head of Regulatory	Jun 03 '26	Sale	2.93	192	563	67,611	Jun 04 08:35 PM
Thomas John	Director	Jun 01 '26	Sale	2.98	10,000	29,801	472,784	Jun 02 08:35 PM
JOHNNY THOMAS	Officer	Jun 01 '26	Proposed Sale	3.05	10,000	30,500		Jun 01 04:32 PM
Yu Yong	Chief Scientific Officer	May 11 '26	Sale	2.97	605	1,798	149,706	May 12 08:30 PM
Cappello Joseph	Chief Technical Officer	May 11 '26	Sale	2.97	605	1,799	154,549	May 12 08:30 PM
Zindrick Thomas	President and CEO	May 11 '26	Sale	2.94	2,798	8,226	532,051	May 12 08:30 PM
Smalling Ralph	Head of Regulatory	May 11 '26	Sale	2.98	270	804	67,803	May 12 08:30 PM
Smalling Ralph	Head of Regulatory	Mar 24 '26	Sale	2.42	345	835	68,313	Mar 26 05:00 PM
Smalling Ralph	Head of Regulatory	Mar 25 '26	Sale	2.51	240	602	68,073	Mar 26 05:00 PM
Cappello Joseph	Chief Technical Officer	Mar 24 '26	Sale	2.42	906	2,193	155,154	Mar 26 05:00 PM
Yu Yong	SVP, Clinical Development	Mar 24 '26	Sale	2.42	906	2,193	144,938	Mar 26 05:00 PM
Zindrick Thomas	President and CEO	Mar 24 '26	Sale	2.42	3,582	8,668	534,849	Mar 26 05:00 PM
Thomas John	Director	Mar 02 '26	Sale	2.90	10,000	28,957	482,784	Mar 03 08:05 PM
JOHNNY THOMAS	Officer	Mar 02 '26	Proposed Sale	2.98	10,000	29,800		Mar 02 04:32 PM
Yu Yong	SVP, Clinical Development	Nov 17 '25	Sale	5.37	973	5,224	145,844	Dec 11 08:50 PM
Zindrick Thomas	President and CEO	Nov 17 '25	Sale	5.37	4,509	24,211	538,431	Dec 11 08:50 PM
Cappello Joseph	Chief Technical Officer	Nov 17 '25	Sale	5.37	973	5,224	156,060	Dec 11 08:49 PM
Smalling Ralph	Head of Regulatory	Nov 17 '25	Sale	5.37	343	1,842	68,823	Dec 09 08:00 PM
Smalling Ralph	Head of Regulatory	Dec 05 '25	Sale	4.69	165	774	68,658	Dec 09 08:00 PM
Thomas John	Director	Dec 01 '25	Sale	5.00	10,000	50,008	492,784	Dec 02 07:00 PM
JOHNNY THOMAS	Director	Dec 01 '25	Proposed Sale	5.56	10,000	55,600		Dec 01 04:34 PM

NAMS

NewAmsterdam Pharma Company NV

GNLX

Genelux Corp

Upgrade your Finviz experience